Atossa Therapeutics (ATOS) Non Operating Income (2015 - 2018)
Atossa Therapeutics (ATOS) posted quarterly Non Operating Income of $104.0 for Q3 2018, up 136.75% year-over-year from $43.93 in Q3 2017, and up 76.27% quarter-over-quarter from $59.0 in Q1 2018.
Atossa Therapeutics (ATOS) Non Operating Income (2015 - 2018) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Non Operating Income for 4 consecutive years, with $104.0 the latest figure, recorded in Q3 2018.
- In Q3 2018, Non Operating Income rose 136.75% year-over-year to $104.0; the TTM figure through Sep 2018 stood at -$83.0 (down 100.0% YoY), while the FY2015 annual figure was $431.0, up 65.77% from the prior year.
- Non Operating Income rose to $104.0 in Q3 2018 per ATOS's latest filing, from $59.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $1.8 million in Q3 2016 and bottomed at -$115677.0 in Q4 2015.
- Historically, Non Operating Income has averaged $195995.3 across 4 years, with a median of $59.0 in 2018.
- Annual changes were most pronounced in 2016 — Non Operating Income jumped 2442.36% — and 2017, when it tumbled 100.02%.
- Atossa Therapeutics' Non Operating Income stood at -$115677.0 in 2015, then soared by 1624.18% to $1.8 million in 2016, then sank by 100.02% to -$283.0 in 2017, then soared by 136.75% to $104.0 in 2018.
- Business Quant data shows ATOS's Non Operating Income at $104.0 in Q3 2018, $59.0 in Q1 2018, and -$283.0 in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 104.00 |
| Mar 31, 2018 | 59.00 |
| Sep 30, 2017 | -283.00 |
| Mar 31, 2017 | 37.00 |
| Sep 30, 2016 | 1.76 Mn |
| Dec 31, 2015 | -115,677.00 |
| Sep 30, 2015 | 69,350.00 |
| Jun 30, 2015 | 48,659.00 |
| Mar 31, 2015 | -1,415.00 |